LXs are known to release pro-survival soluble molecules, reduce the synthesis and release of pro-inflammatory mediators, and inhibit inflammation, tumor cell proliferation, growth, and tumor invasiveness in part by the inhibition of autocrine TGF-β1 signaling [215] or by blocking the ROS/ERK/MMP pathway [216] in pancreatic cancers. Here, TGFB1 is linked to neoplasm.